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Dr Curtis G. Tribble (Gainesville, Fla). I have been handing
out Dr Bruce Lytle’s single–authored essay on this subject that
was published in the Annals of Thoracic Surgery about 5 years
ago to most of my junior house officers and students ever since
he wrote it. It is a great article for anybody who would like to
read about his thoughts at that time. His last sentences in that article
state that (1) coronary artery bypass surgery is best for most of these
patients with ischemic cardiomyopathy, (2) we do not know very
much about any of the other options, and (3) the other options
should be studied. Today’s article presented by Mr Yoon is obvi-
ously an attempt to address that charge.
I have to admit, as a former English major, that I was a bit dis-
tracted and even fascinated by the language of this article, such292 The Journal of Thoracic and Cardiovascular Surgas the ‘‘split–sample holdout.’’ I am not going to ask you this, Dus-
tin, but don’t you think that sounds more like a poker game than
a statistical test? Other terms were equally interesting, such as the
‘‘parsimonious variable selection,’’ ‘‘the bagging bootstrap aggre-
gation,’’ and my favorite term in the article, ‘‘the cognitive prosthe-
sis tool.’’ But all kidding aside, I did round up a real statistician and
ask for some help in understanding all these terms, and I did learn,
as I would have expected, that all these terms are not only real but
quite valid statistical strategies.
I will also say that it is obvious that this study was a good-faith
effort to answer Dr Lytle’s earlier call for more clarity on the op-
tions for ischemic cardiomyopathy. There are lots of patients, there
are hard end points, and there, indeed, are valid statistical strategies.
However, one of my difficulties in thinking about this article is that
clearly not all the options are truly available to all the patients, and,
presumably, some thoughtful person made the original choice
based on literally tens if not hundreds of bits of data, surely some
of which are unknown to the later reviewer and, thus, difficult to
study.
So to think more specifically about some of the numbers, it
seems to me that although 75% of the total group of 1321 patients
were well served by coronary artery bypass alone (n ¼ 556) or by
transplantation (n ¼ 423), less than 4% (n ¼ 50) were well served
by mitral valve repair combined with coronary bypass. I think this
is a sobering assertion and leads me to my one question for you,
Dustin, that you might have some insight into from your study
along with other recent studies from your institution, such as
Mark Gillinov’s article presented at this meeting last year compar-
ing mitral valve repair and mitral valve replacement in older pa-
tients, in which survival was not altered by the technique of
treating the mitral valve.
Here is my question. Given that your model suggests that mitral
valve repair should be done in so few patients with ischemic mitral
regurgitation, do you think that it is possible that the patients with
ischemic mitral valve regurgitation would have been better served
with an mitral valve replacement instead of a mitral valve anulo-
plasty if this were done with the techniques of modern cardiac pro-
tection and chordal preservation, or is it the sense of you and your
colleagues at the Cleveland Clinic that the regurgitant mitral valve
in the setting of ischemic cardiomyopathy is best treated medically
in the vast majority of cases?
Mr Yoon. Thank you very much for your comments and your
question, Dr Tribble.
When we went back and analyzed alternative survival compar-
isons for CABG alone, CABG with concomitant SVR, and trans-
plantation therapies, we found that mitral valve anuloplasty was
recommended as the best therapy to optimize survival less than
2% of the time. As you say, these are sobering statistics, and I
think they may provide some insight into which options have
the best long-term outcomes. Mitral valve anuloplasty may not
be the best option for these patients with ischemic mitral valve
etiology.
In terms of Dr Gillinov’s paper presented here last year, he
looked at 195 propensity-matched pairs undergoing replacement
versus repair for degenerative mitral valve disease and found no
major survival difference between these 2 groups. Neither mitral
valve repair nor replacement emerged as a risk factor that affected
overall survival.ery c February 2010
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DWe think that a common thread in all these studies is that, in
these sicker patients with ischemic cardiomyopathy and multiple
comorbidities, prognosis is poor whether you do replacement or re-
pair. I believe that it will require a randomized trial to further elu-
cidate these types of outcomes. My mentor, Dr Blackstone, has
informed me that in July, the Cardiac Surgery Network plans to
conduct a randomized trial looking specifically at these outcomes,
at moderate and severe mitral regurgitation, and at the effects of
repair versus replacement. The results will hopefully settle some
of the controversy surrounding treatment options.
Dr Paul Kurlansky (Miami, Fla). This is a very provocative
and interesting study. I look forward to the complete article to try
to understand it better. I would like to exercise a word of caution,
though, and perhaps it is related to the number of patients included
and the number of variables that were available to you. In the exam-
ple that you presented, a patient who had a certain risk-factor profile
with lifestyle problems and smoking, lifestyle problems that led to
diabetes as well as cigarette smoking, put him into the transplanta-
tion category. I think that shows probably one of the shortcomings
of this approach because likely somebody who has lifestyle prob-
lems and smoking might not be an ideal candidate for transplanta-
tion and might not be accepted for transplantation.
Therefore, I think we wind up with a situation in which our clin-
ical judgment might be even better than what the figures would sug-
gest, and I was sort of wondering how you might solve some of
these problems. Perhaps it might be wiser to view this sort of study
as hypothesis generating rather than definitive.
Mr Yoon. Thank you very much for your comment, Dr Kurlan-
sky. I think your point is well taken, and it is in fact the reason we
used the term ‘‘decision support tool’’ rather than ‘‘decision mak-
ing tool.’’ In complex, real-world scenarios, I think a tool like this
can synergistically augment a surgeon’s capabilities by allowing
not just 1 or 2 clinical variables to be taken into account when rec-
ommending the optimal surgical therapy but rather 3, 4, 5, or, in our
case, hundreds of preoperative variables and their transformations.
This is difficult for surgeons to fully assimilate, and studies have
shown that clinicians usually think of the average result when it
comes to variables, and not necessarily the magnitude. A support
tool can help tremendously in this aspect.
In terms of applicability of each therapy, I think your point is
also well taken in that not all of our patients were eligible for every
treatment option. We tried to correct for this by setting eligibility
criteria for our patient population. For example, to be eligible for
SVR, a patient had to have anterior akinesia or dyskinesi, and
also a left ventricular end diastolic diameter greater than 6 cm. In
fact, the STICH trial eligibility to enter the study was based on an-
terior akinesia or dyskinesia amenable to SVR and an ejection frac-
tion of 35% or less. For transplantation, our patients had to be in
New York Heart Association functional class III or IV, be less
than 70 years old, and have a serum creatinine level of less than
1.7 mg/dL. These broad criteria were set up to include all possible
choices that an individual could have and not necessarily that they
should undergo that particular surgery. The guidelines are just
that—a possible path. The surgeon would make the final decision
based on all available clinical information, imaging results, and fi-
nal inspection in the operating room.
Dr John V. Conte, Jr (Baltimore, Md). I would like to congrat-
ulate you on a flawlessly presented article, and I would like toThe Journal of Thoracic and Cacommend your mentors and co-authors on helping you to prepare
such a nice presentation. I know how much work it takes, and I
think this kind of mentoring is what we need to do more of in
our specialty, particularly allowing junior members of our profes-
sion to present at national meetings.
The one comment I would like to make other than congratulating
you and your co-authors is that this is a very intriguing article; how-
ever, the hypothesis does not help many people with decision mak-
ing in the real world. The reality is we do not have transplantation as
an option that is readily available at the times that we often would
like for such patients, and also your inclusion of patients undergo-
ing SVR who had an infarction as recently as 30 days also does not
correlate with what we would generally recommend. We would not
perform that operation for most patients who have had an infarction
that recently.
Those limitations being noted, I think it does provide questions
for us when we are selecting options for our patients, and again, I
want to congratulate you on a nice job.
Mr Yoon. Thank you very much, Dr Conte. As part of our
inclusion criteria, all patients in the study had a myocardial infarc-
tion greater than 30 days before surgery. In our SVR population,
the median time between infarction and surgery was 3 years, so
your point is valid. The decision to pursue SVR includes MRI
studies, viability, and final inspection in the operating room,
some factors that we did not and cannot incorporate into our
models. Also, you are absolutely right that fewer than 10% of el-
igible recipients actually receive a heart transplantation. This is
the reason we need to evaluate other treatment options for cardio-
myopathy and know, as best as possible, the risks and survival
benefits of these alternative treatments. Clearly, all the issues
you raise are important.
DrCharles C. Canver (Riyadh, Saudi Arabia). This is a very in-
triguing article. When I began to listen, I was hoping that you were
going to come up with a model, almost a calculator, that would help
to solve this complex problem.As you know, ischemic cardiomyop-
athy is a syndrome that cannot be caused by a single process. Unfor-
tunately, this model is not capable of really answering the clinical
questions. In reality, the decision is made by the use of many tests
that assesses the viability of the myocardium in light of the patient’s
symptoms. Furthermore, I had difficulty accepting that your
51-year-old patient with a 4þMR and 10% ejection fraction could
be best treated with CABG alone. In the actual clinical setting, I
do not think anybody would tackle that problem with CABG alone.
I am very intrigued by young individuals, such as yourself, who
are trying to bring new preoperative calculation methods to help us
make a better decision in complex clinical dilemmas. Although that
is a very nice thing to do, I am still skeptical. Your clinical model
certainly does not address the real clinical issues. However, I do
want to congratulate you for your nice work.
Mr Yoon. Again, with this decision support tool, we have made
small but significant steps toward a clinical tool that can be
accurately and reliably used in the clinical setting. In the future,
we will continue trying to elucidate these many and variable factors
that surgeons must deal with in the real clinical world. We also
anticipate prospective and external validation of our tool and will
take steps for its generalizability to the outside population. Thank
you for your comments, Dr Canver; I will definitely keep them in
mind.rdiovascular Surgery c Volume 139, Number 2 293
